Opinion on Therapy Area in South and Central America

Published within

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Amarin: RNA therapy results announced to attract suitors

In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

AIDS 2010: promising developments for novel HIV agents and strategies

Given the abundance of therapeutic options for HIV treatment, companies are increasingly looking to simplify therapy through the development of cross-class combinations and nucleoside-sparing strategies to minimize toxicity. Many of the pipeline drugs highlighted at this year's International AIDS Conference brought this new direction of development into focus.

Published By Datamonitor
27 Jul 2010
ResearchWire
ResearchWire

Advanced Life Sciences: aiming for second place with cethromycin

Published By Datamonitor
30 Jun 2006
Expert View
Expert View

Adult acute leukemia: demand for innovative drugs that prolong survival

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.

Published By Datamonitor
11 May 2006
ResearchWire
ResearchWire

ADHD: immature adult market continues to offer greatest commercial potential

Published By Datamonitor
14 May 2008
Expert View
Expert View

AD/PD 2011: far too early to lay beta-amyloid hypothesis to rest

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of pipeline Alzheimer's drugs.

Published By Datamonitor
24 Mar 2011
Expert View
Expert View

AD/PD 2011: Alzheimer's companies showcase new data for marketed brands

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of currently marketed treatments for both diseases.

Published By Datamonitor
24 Mar 2011
ResearchWire
ResearchWire

Acute stroke: AstraZeneca drug candidate offers blockbuster potential

Published By Datamonitor
31 Aug 2006
CommentWire
CommentWire

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor
28 Jan 2011

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

No help is available.